2014版本肿瘤呕吐指南.pptVIP

Click to edit Master title style 发生CINV的概率主要取决于2个因素：患者特征和化疗——特异性因素。1 1. Navari RM. J Support Oncol. 2003;1(2):89–103. * The aprepitant triple-therapy is recommended for the acute phase of HEC, and the two combination including aprepitant for the delayed phase of HEC. These recommendation also suitable for the high risk MEC pts, who are receiving certain chemotherapy drugs, such as carbopaltin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, or methotrexate, etc. The detailed information would be introduced in the medical MAP. Recent guidelines published incorporate recommendatio